DDrare: Database of Drug Development for Rare Diseases

95. 自己免疫性肝炎
［臨床試験数：44，薬物数：57（DrugBank：26），標的遺伝子数：18，標的パスウェイ数：108］

Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZATHIOPRINE; Abatacept; Anti-BAFFR antibody; Anti-BAFFr antibody; Azathioprine; Budesonide; Calcium; Cannabidiol; Chloroquine; Chloroquine diphosphate; Chloroquine diphosphate 250mg; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine-A; Denosumab; EFALIZUMAB; Efalizumab; Erythropoietin; Gold; High protein high fiber diet; INTERLEUKIN 2; Ianalumab; Inflectra (Infliximab); Infliximab; Interleukin 2; JKB-122; JKB-122 in capsule or tablet form; LCP-Tacro (tacrolimus); MYCOPHENOLATE MOFETIL; Metronidazole; Minodronic acid; Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofeti; Mycophenolate mofetil; Orbcel-C; Orencia® (Abatacept); PREDNISOLONE SODIUM SUCCINATE; Prednisolone; Prednisone; Preimplantation factor; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Regulatory T cells; Risedronic acid; SPIF; Synthetic PreImplantation Factor; Tacrolimus; Treatment with azathioprin; Treatment with mycophenolat mofetil; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ursodeoxycholic acid combination of immunosuppressive agents; VAY736; Vitamin D; Zoledronic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03842254 (ClinicalTrials.gov)	January 25, 2019	12/2/2019	Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease	Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease	Autoimmune Hepatitis	Drug: Erythropoietin	Northwestern University	Mount Sinai Hospital, New York;Icahn School of Medicine at Mount Sinai	Enrolling by invitation	18 Years	74 Years	All	10	Early Phase 1	United States
2	NCT02704338 (ClinicalTrials.gov)	April 2016	28/2/2016	Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis	Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in Autoimmune Hepatitis	Autoimmune Diseases	Biological: Regulatory T cells	Nanjing Medical University	NULL	Not yet recruiting	10 Years	70 Years	Both	30	Phase 1;Phase 2	NULL
3	NCT01988506 (ClinicalTrials.gov)	January 6, 2014	7/11/2013	Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases	Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach	Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis	Drug: Interleukin 2	Assistance Publique - Hôpitaux de Paris	Iltoo Pharma	Active, not recruiting	18 Years	N/A	All	81	Phase 2	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03842254
(ClinicalTrials.gov)

January 25, 2019

12/2/2019

Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease

Autoimmune Hepatitis

Drug: Erythropoietin

Northwestern University

Mount Sinai Hospital, New York;Icahn School of Medicine at Mount Sinai

Enrolling by invitation

18 Years

74 Years

All

Early Phase 1

United States

NCT02704338
(ClinicalTrials.gov)

April 2016

28/2/2016

Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis

Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in Autoimmune Hepatitis

Autoimmune Diseases

Biological: Regulatory T cells

Nanjing Medical University

NULL

Not yet recruiting

10 Years

70 Years

Both

Phase 1;Phase 2

NULL

NCT01988506
(ClinicalTrials.gov)

January 6, 2014

7/11/2013

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach

Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis

Drug: Interleukin 2

Assistance Publique - Hôpitaux de Paris

Iltoo Pharma

Active, not recruiting

18 Years

N/A

All

Phase 2

France